Bristol Myers Squibb: Admilparant Succeeds in Phase III, but the Higher Dose Fails to Reach Statistical Significance
Bristol Myers Squibb announced topline results from ALOFT-IPF, a Phase III trial involving approximately 1,255 patients with idiopathic pulmonary fibrosis.
The investigational LPA1 receptor antagonist admilparant, administered at 60 mg twice daily, achieved a statistically significant improvement versus placebo in absolute forced vital capacity change at Week 52. The 120 mg twice-daily dose did not achieve statistical significance, although the company reported numerical benefit.
Discontinuations due to adverse events were described as low and comparable with placebo. Detailed efficacy estimates, confidence intervals, and complete safety data have not yet been published. Bristol Myers Squibb News
Primary source: BMS Phase III announcement — October 12
Why it matters strategically
The positive 60 mg result provides evidence supporting the therapeutic potential of LPA1 inhibition.
However, the failure of the higher dose to reach statistical significance creates an important interpretive question.
Does the apparent absence of a conventional dose-response relationship reflect pharmacology, statistical variability, exposure differences, or an unrecognized limitation in the trial?
The answer matters for regulatory submissions and competing development programs.
Another important consideration is that the IPF treatment landscape has changed.
Boehringer Ingelheim received FDA approval for nerandomilast, marketed as Jascayd, in October 2025. Its pivotal trials demonstrated reductions in FVC decline.
Consequently, admilparant's future commercial position must be evaluated against an evolving treatment landscape rather than only against older antifibrotics. GlobeNewswire
BBIU interpretation: A statistically successful pivotal trial does not automatically establish commercial differentiation.
